AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. It discovers, develops, manufactures, and commercializes prescription medicines across key therapy areas including oncology; cardiovascular, renal and metabolism; respiratory and immunology; vaccines and immune therapies; and rare diseases (via Alexion).
From a manufacturing and process perspective, AstraZeneca’s operations cover small-molecule active pharmaceutical ingredients and finished dosage forms, as well as biologics such as monoclonal antibodies and other protein therapeutics. The company maintains a worldwide network for process development, scale-up, sterile fill–finish, and packaging, supported by extensive in-house research and external collaborations. Its activities connect advanced chemistry, bioprocess engineering, and quality-controlled GMP production to supply medicines globally.
chemXplore tracks 1 project involving AstraZeneca.
AstraZeneca's role on them: Owner.
Tarlatamab (IMDELLTRA) plus durvalumab showed statistically significant OS, PFS and ORR benefits versus durvalumab alone in Phase 3 DeLLphi‑305 for first‑line maintenance ES‑SCLC.
Phase 3 CROSSING shows histologic remission and improved dysphagia at week 24 with benefits sustained through week 52 in symptomatic, uncontrolled eosinophilic esophagitis.
First FDA-cleared IHC companion diagnostic to detect PTEN protein loss and select patients for capivasertib (TRUQAP) plus abiraterone therapy.
Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16
BLA for ifinatamab deruxtecan accepted and granted FDA Priority Review for adult ES‑SCLC post‑platinum therapy; PDUFA Oct 10, 2026. Based on IDeate‑Lung01 Phase 2 (B7‑H3 DXd ADC).
FDA approves all-oral, fixed-duration regimen for CLL, reducing treatment time. AMPLIFY study shows 35% lower risk of progression or death compared to chemoimmunotherapy.
Séverine Lemoine will lead operations in France, focusing on product launches and expanding the local presence in oncology.
Galán praises UK's regulatory stability and plans to double investments, enhancing local supply chains and jobs, while supporting UK-EU cooperation on electrification and energy security.
By country, the most active first. active / all projects
